Paul Wayne Armstrong

Paul Wayne Armstrong

Auto-generated profile, based on publicly available information

Paul Wayne Armstrong

Canadian VIGOUR Centre, University of Alberta , 4-120 Katz Group Centre for Pharmacy and Health Research, Edmonton, Alberta , T6G 2E1

Research Focus & Metrics

Academic Career Length

57Years (1970-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2015 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
JGJennifer B. Green
Jennifer B. Green
MBM. Angelyn Bethel
M. Angelyn Bethel
PAPaul W. Armstrong
Paul W. Armstrong
JBJohn B. Buse
John B. Buse
SESamuel S. Engel
Samuel S. Engel
RHRury R. Holman
Rury R. Holman
Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching individually appropriate glycemic targets in all patients. To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The primary cardiovascular outcome was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. During a median follow-up of 3.0 years, there was a small difference in glycated hemoglobin levels (least-squares mean difference for sitagliptin vs. placebo, −0.29 percentage points; 95% confidence interval [CI], −0.32 to −0.27). Overall, the primary outcome occurred in 839 patients in the sitagliptin group (11.4%; 4.06 per 100 person-years) and 851 patients in the placebo group (11.6%; 4.17 per 100 person-years). Sitagliptin was noninferior to placebo for the primary composite cardiovascular outcome (hazard ratio, 0.98; 95% CI, 0.88 to 1.09; P<0.001). Rates of hospitalization for heart failure did not differ between the two groups (hazard ratio, 1.00; 95% CI, 0.83 to 1.20; P=0.98). There were no significant between-group differences in rates of acute pancreatitis (P=0.07) or pancreatic cancer (P=0.32). Among patients with type 2 diabetes and established cardiovascular disease, adding sitagliptin to usual care did not appear to increase the risk of major adverse cardiovascular events, hospitalization for heart failure, or other adverse events. (Funded by Merck Sharp & Dohme; TECOS ClinicalTrials.gov number, NCT00790205.)

3 August 2004 in Circulation
Verified
Journal Article
Closed access
WMWriting Committee Members
Writing Committee Members
EAElliott M. Antman
Elliott M. Antman
DADaniel T. Anbe
Daniel T. Anbe
PAPaul Wayne Armstrong
Paul Wayne Armstrong
EBEric R. Bates
Eric R. Bates
AJAlice K. K. Jacobs
Alice K. K. Jacobs

7 July 2011 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
COC.M. O'COnnor
C.M. O'COnnor
RSR.C. Starling
R.C. Starling
AHA.F. Hernandez
A.F. Hernandez
PAP.W. Armstrong
P.W. Armstrong
KDK. Dickstein
K. Dickstein
RCR.M. Califf
R.M. Califf
Nesiritide is approved in the United States for early relief of dyspnea in patients with acute heart failure. Previous meta-analyses have raised questions regarding renal toxicity and the mortality associated with this agent. We randomly assigned 7141 patients who were hospitalized with acute heart failure to receive either nesiritide or placebo for 24 to 168 hours in addition to standard care. Coprimary end points were the change in dyspnea at 6 and 24 hours, as measured on a 7-point Likert scale, and the composite end point of rehospitalization for heart failure or death within 30 days. Patients randomly assigned to nesiritide, as compared with those assigned to placebo, more frequently reported markedly or moderately improved dyspnea at 6 hours (44.5% vs. 42.1%, P=0.03) and 24 hours (68.2% vs. 66.1%, P=0.007), but the prespecified level for significance (P≤0.005 for both assessments or P≤0.0025 for either) was not met. The rate of rehospitalization for heart failure or death from any cause within 30 days was 9.4% in the nesiritide group versus 10.1% in the placebo group (absolute difference, −0.7 percentage points; 95% confidence interval [CI], −2.1 to 0.7; P=0.31). There were no significant differences in rates of death from any cause at 30 days (3.6% with nesiritide vs. 4.0% with placebo; absolute difference, −0.4 percentage points; 95% CI, −1.3 to 0.5) or rates of worsening renal function, defined by more than a 25% decrease in the estimated glomerular filtration rate (31.4% vs. 29.5%; odds ratio, 1.09; 95% CI, 0.98 to 1.21; P=0.11). Nesiritide was not associated with an increase or a decrease in the rate of death and rehospitalization and had a small, nonsignificant effect on dyspnea when used in combination with other therapies. It was not associated with a worsening of renal function, but it was associated with an increase in rates of hypotension. On the basis of these results, nesiritide cannot be recommended for routine use in the broad population of patients with acute heart failure. (Funded by Scios; ClinicalTrials.gov number, NCT00475852.)

7 December 1999 in Circulation
Verified
Journal Article
Closed access
PDF file
MPMilton Packer
Milton Packer
PPPhilip A. Poole-Wilson
Philip A. Poole-Wilson
PAPaul W. Armstrong
Paul W. Armstrong
JCJohn George Franklin Cleland
John George Franklin Cleland
John HorowitzJohn Horowitz
John Horowitz
BUBarry F. Uretsky
Barry F. Uretsky
Background —Angiotensin-converting enzyme (ACE) inhibitors are generally prescribed by physicians in doses lower than the large doses that have been shown to reduce morbidity and mortality in patients with heart failure. It is unclear, however, if low doses and high doses of ACE inhibitors have similar benefits. Methods and Results —We randomly assigned 3164 patients with New York Heart Association class II to IV heart failure and an ejection fraction ≤30% to double-blind treatment with either low doses (2.5 to 5.0 mg daily, n=1596) or high doses (32.5 to 35 mg daily, n=1568) of the ACE inhibitor, lisinopril, for 39 to 58 months, while background therapy for heart failure was continued. When compared with the low-dose group, patients in the high-dose group had a nonsignificant 8% lower risk of death ( P =0.128) but a significant 12% lower risk of death or hospitalization for any reason ( P =0.002) and 24% fewer hospitalizations for heart failure ( P =0.002). Dizziness and renal insufficiency was observed more frequently in the high-dose group, but the 2 groups were similar in the number of patients requiring discontinuation of the study medication. Conclusions —These findings indicate that patients with heart failure should not generally be maintained on very low doses of an ACE inhibitor (unless these are the only doses that can be tolerated) and suggest that the difference in efficacy between intermediate and high doses of an ACE inhibitor (if any) is likely to be very small.

1 August 2004 in JACC
Verified
Journal Article
Closed access
EAElliott M. Antman
Elliott M. Antman
DADaniel T. Anbe
Daniel T. Anbe
PAPaul Wayne Armstrong
Paul Wayne Armstrong
EBEric R. Bates
Eric R. Bates
LGLee A. Green
Lee A. Green
AJAlice K. Jacobs
Alice K. Jacobs

15 January 2008 in Circulation
Verified
Journal Article
Closed access
PDF file
EAElliott M. Antman
Elliott M. Antman
MHMary Hand
Mary Hand
PAPaul W. Armstrong
Paul W. Armstrong
EBEric R. Bates
Eric R. Bates
LGLee A. Green
Lee A. Green
CYClyde W. Yancy
Clyde W. Yancy